Outpatient haploidentical hematopoietic stem cell transplant using post-transplant cyclophosphamide and incidence of hemorrhagic cystitis.

Autor:	Gutiérrez-Aguirre CH; University Hospital 'Dr. José E. González', Universidad Autónoma de Nuevo León, Monterrey, Mexico., Esparza-Sandoval AC; University Hospital 'Dr. José E. González', Universidad Autónoma de Nuevo León, Monterrey, Mexico., Palomares-Leal A; University Hospital 'Dr. José E. González', Universidad Autónoma de Nuevo León, Monterrey, Mexico., Jaime-Pérez JC; University Hospital 'Dr. José E. González', Universidad Autónoma de Nuevo León, Monterrey, Mexico., Gómez-Almaguer D; University Hospital 'Dr. José E. González', Universidad Autónoma de Nuevo León, Monterrey, Mexico., Cantú-Rodríguez OG; University Hospital 'Dr. José E. González', Universidad Autónoma de Nuevo León, Monterrey, Mexico. Electronic address: ogcantur@yahoo.com.mx.
Jazyk:	angličtina
Zdroj:	Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2022 Apr-Jun; Vol. 44 (2), pp. 163-168. Date of Electronic Publication: 2020 Dec 04.
DOI:	10.1016/j.htct.2020.09.149
Abstrakt:	Introduction: Hemorrhagic cystitis (HC) is a common complication of haploidentical hematopoietic stem cell transplantation (haplo-HSCT), characterized by irritative symptoms of the urinary tract and a higher morbidity and mortality rate. The worldwide incidence is reported between 10% and 70%. The use of alkylating agents and BK viral infection are the most frequent etiologies. The aim of this study was to report the HC incidence in an outpatient haplo-HCST program with a reduced intensity-conditioning (RIC) regimen, cataloguing risk factors, complications and final outcomes. Methods: The medical database of patients who received a haplo-HSCT between January 2012 and November 2017 was retrospectively analyzed. Demographic variables, general characteristics and HC incidence were included. Results: One hundred and eleven patients were included, 30 (27%) of whom developed HC, most of them (70%) being grade II, with a 30-day (7-149) median time of post-transplant HC onset. The BK virus was detected in 71% of the urine samples analyzed. All HC patients responded to treatment, except two (6.6%), who died due to HC complications. Conclusions: There was no difference in the HC incidence or severity, compared to that reported when performing haplo-HSCT in hospitalized patients, although the donor-recipient sex mismatch did relate to a higher HC incidence. (Copyright © 2022 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu